VERAXA Biotech AG (NASDAQ: VRXA) provided a corporate and pipeline update on Thursday, highlighting advancements in its proprietary BiTAC(R) platform during the first half of 2026. The company reported that its pipeline now includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate (ADC) programs, and two non-BiTAC assets available for partnering. VERAXA stated it plans to prioritize investment in its BiTAC portfolio while seeking to monetize selected non-BiTAC programs to help finance future development, with the goal of advancing lead BiTAC-TCE candidate VXA-102 to IND/CTA readiness by early 2028.
Company executives also cited strong industry interest in T-cell engager and ADC technologies, noting that recent partnering discussions at the BIO International Convention and other scientific meetings reinforced confidence in the company’s differentiated BiTAC platform and its potential to secure strategic collaborations. VERAXA said it continues to refine both its pipeline and partnering strategy as it advances its next generation of cancer therapies. The full press release is available at https://ibn.fm/xTF5q.
This update underscores VERAXA’s commitment to its BiTAC platform, which is designed to overcome limitations of conventional T-cell engagers. By prioritizing BiTAC programs and exploring partnerships for non-BiTAC assets, the company aims to accelerate development while managing costs. The BiTAC platform, founded on scientific breakthroughs at the European Molecular Biology Laboratory (EMBL), represents a novel approach to antibody-based therapeutics. VERAXA’s strategy reflects a broader industry trend toward bispecific antibodies and ADCs, which are gaining traction as potent cancer therapies.
The company’s progress in advancing VXA-102 toward regulatory filings is a key milestone, as it could potentially enter clinical trials in 2028 if successful. The growing interest from pharmaceutical partners, as evidenced by discussions at major conferences, suggests that VERAXA’s technology may address unmet needs in oncology. For more information about VERAXA and its pipeline, visit the company’s newsroom at http://ibn.fm/VRXA.
VERAXA Biotech AG is building a premier engine for discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Powered by transformative technologies and guided by quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at EMBL.
